Antibiotic treatment for heart device infections
Part of Heart & circulation, Infections clinical trials.
This study tests a new antibiotic called oritavancin for treating skin infections at the site of heart devices like pacemakers or defibrillators, especially when caused by drug-resistant bacteria. The goal is to see if this once-daily antibiotic works as well as the standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You should have signs of a skin infection at your heart device (pacemaker or defibrillator) site, like redness, pain, swelling, or discharge.
- Your infection needs to be caused by certain bacteria (like staph or strep) that are resistant to common antibiotics, or you need to have a severe penicillin allergy.
- You cannot have an infection caused by other types of bacteria or by bacteria that are resistant to the study drug.
- You must not be pregnant or breastfeeding.
- You must be able to take blood thinners (heparin) or switch to a different blood thinner during the study if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibiotic called oritavancin for treating serious heart infections caused by certain bacteria. It may offer a simpler treatment option for patients who are already on antibiotics and stable.
This trial tests whether a treatment without rifampin works as well as one with rifampin for a type of heart valve infection caused by staph bacteria. It aims to find a simpler and safer option for patients with an infected artificial heart valve.
This trial measures how your body handles certain intravenous antibiotics used for endocarditis, an infection of the heart valves. It may help doctors understand the best antibiotic dosing for people with valve infections.
This trial tests whether a shorter course of antibiotics is as safe and effective as the standard longer course for people who have had an infected heart device removed. It aims to reduce side effects and make treatment easier.
This study tests a new antibiotic called dalbavancin for treating infections of the heart valves. It may offer a simpler treatment option with fewer hospital visits.
This trial compares taking antibiotics by mouth versus receiving antibiotics through a vein (outpatient IV) for an infection of the heart valve. It’s designed to see whether the oral option can work as well and safely, especially after initial treatment and surgery if needed.
Hear when a new Infective Endocarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.